ByteDance's drug unit showed an AI-designed IL-17 inhibitor at a Boston conference. The molecule targets interactions pharma called undruggable. Only trials will tell.
Temporary teams can build new systems, but permanent ones can both develop them and manage them after launch. by Ryan Nelson and Thomas H. Davenport In 2011, The New York Times was facing declines in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results